After-hours movers: Palantir, Hims & Hers Health, Sarepta Therapeutics, Sanmina
After-hours movers:
Palantir (NASDAQ: PLTR) rose 2% after reporting solid quarterly results and better than expected guidance. Palantir sees Q4 2025 revenue of $1.327-1.331 billion, versus the consensus of $1.18 billion.
Hims & Hers Health (NYSE: HIMS) rose 7% despite mixed results, after disclosing talks with Novo Nordisk (NYSE: NVO) to offer Wegovy treatments. The company emphasized that the discussions remain ongoing and no definitive agreement has been executed.
Sarepta Therapeutics (NASDAQ: SRPT) fell 22% after it reported completion of its ESSENCE confirmatory study for AMONDYS 45 and VYONDYS 53, treatments for Duchenne muscular dystrophy. While the study did not achieve statistical significance on its primary endpoint of 4-step ascend velocity at 96 weeks, Sarepta reported positive trends favoring treatment over placebo. The company posted third-quarter net product revenues of $370.0 million.
Sanmina (NASDAQ: SANM) climbed 18% after results beat estimates and it gave blowout guidance. Sanmina sees Q1 2026 revenue of $2.9-3.2 billion, versus the consensus of $2.13 billion.